Roland Griffiths
Professor of Neuroscience and Psychiatry
Data updated
Research Footprint
Roland Griffiths appears in 69 tracked papers (2006–2026) and 1 clinical trial, most studied alongside Psilocybin, LSD and Ayahuasca, across Anxiety Disorders, Depressive Disorders and Substance Use Disorders (SUD).
Most-cited paper: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer (2144 citations).
Frequent co-authors: Matthew Johnson, Frederick Barrett and Alan Davis.
Background & Research
Roland Griffiths (1946–2023) was a titan of psychopharmacology at Johns Hopkins University. He is credited with initiating the modern era of psychedelic research with his landmark 2006 study on psilocybin and mystical experiences. His career spanned over 50 years, during which he founded the Johns Hopkins Center for Psychedelic and Consciousness Research and led groundbreaking trials for cancer-related distress and smoking cessation.
Key Impact
Seminal figure in the modern 'psychedelic renaissance' and founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research.
Collaboration Network
43 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Roland Griffiths is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.
View stakeholder →